News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Pharm-Olam International Ltd. Announces Formation of Rescue Start-Up Team



10/28/2008 3:49:28 PM

HOUSTON, TX Oct. 28, 2008. Pharm-Olam International (POI) a multi-national, full service CRO to the pharmaceutical and biotech industries announces the formation of a Rescue Start-up Team (RST) to assist sponsors with challenging ongoing studies.

“Many CROs have a specialist team to start-up planned studies, but rescue work requires a different strategy to meet tight deadlines and recover lost time. The RST strategy was formalized from our experiences rescuing multiple studies in the last two years”, said Iain Gordon, Vice President of Commercial and Corporate Affairs.

The RST quickly analyzes options for enrollment including: additional countries, new sites within existing countries, and assessing active sites with potential for improvement. After assessment, the plan is initiated by specialists who work in parallel to achieve regulatory approval, site agreements and logistical requirements for the study.

“Pharm-Olam has started a few rescue studies with the RST formally in place and we have averaged a three week reduction from the time we are awarded work to the first site initiation visit”, said Gordon. “We have more than 40 countries to choose from when we implement a rescue plan. From India to Argentina and from South Africa to Romania we can provide options with suitable regulatory environments and patient availability for almost every trial.”

POI provided supplemental enrollment for more studies between 2007 and 2008 than in any previous year, recruiting patients in over 25 countries including India, Poland, Serbia, Mexico, USA and Romania.

For more information please contact iain.gordon@pharm-olam.com

About Pharm-Olam International

Pharm-Olam International is a multi-national contract research organization offering a wide range of comprehensive, clinical research services to the pharmaceutical, biotechnology and medical device industries. From Phase I to Phase IV, POI focuses on delivering the highest quality data, achieving targeted enrollment and meeting projected timelines.


Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES